Studies have also underlined a role for MAPKα/β kinases and activating transcription factor 2 (ATF2) in antagonizing Her2 signaling early in cancer progression, and a role of ATF2-mediated blockade of β-catenin activity. Here, ERBB2 is linked to cancer.